Spero Therapeutics COO Timothy Keutzer to retire effective December 31, 2026
Spero disclosed in an SEC filing that its chief operating officer will step down at year end and remain as a paid consultant into early 2027.
Spero Therapeutics, Inc. disclosed in an 8-K filing dated October 27, 2026 that Timothy Keutzer, the company's Chief Operating Officer, will retire effective December 31, 2026.1 The announcement itself was made on October 26, 2026.
Following his departure, Spero plans to keep Keutzer on in an advisory capacity. The company expects to sign a consulting agreement with him around the effective date, under which he would help with the transition through roughly the end of February 2027, though either side could end the arrangement early with fifteen days' written notice.1 Under the terms of that consulting agreement, Keutzer will be compensated at an hourly rate for the work he performs during this period.1
The filing noted that Keutzer's retirement comes after 11 years with the company.1
The 8-K was signed on October 27, 2026 by Esther Rajavelu, who holds the titles of Chief Executive Officer and Chief Financial Officer at Spero.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.